Examine Title: Efficacy and security of atezolizumab plus cabozantinib vs cabozantinib alone after development with prior immune checkpoint inhibitor therapy in metastatic renal cell carcinoma: major PFS evaluation from the Section 3, randomized, open-label CONTACT-03 research
Publication: ASCO Annual Assembly: Summary LBA4500, Oral Summary Session: Genitourinary Most cancers – Kidney and Bladder – Monday, June 5, 2023, 12:30 pm ET
The Lancet: Monday, June 5, 2023, 8:00 am ET
Dana-Farber Most cancers Institute presenting writer: Toni Ok Choueiri, MD
Metropolis of Hope senior writer: Sumanta Ok. Pal, MD
Abstract:
Sufferers with superior kidney most cancers are routinely given immune checkpoint inhibitors (ICIs) as first-line therapy. The CONTACT-03, section 3 scientific trial examined the consequences of giving ICIs once more, as a part of a typical second-line remedy. It’s the first trial of its type to match a typical remedy alone (cabozantinib) to straightforward remedy plus an ICI (atezolizumab plus cabozantinib) in strong tumors which have progressed after first-line remedy with an ICI. Sufferers taking atezolizumab plus cabozantinib didn’t expertise longer development free survival or general survival in contrast with these taking cabozantinib alone. An examination of subgroups of sufferers primarily based on prior therapy regimens and threat teams confirmed no good thing about the addition to any group. Additional, sufferers taking the mixture remedy skilled increased ranges of toxicity.
Affect:
Immune checkpoint inhibitors comparable to those who block PD-1 and PD-L1 have revolutionized most cancers remedy and turn into a part of customary first-line remedy for a lot of strong tumors, together with for superior kidney most cancers. An rising apply for these sufferers consists of persevering with or rechallenging with these medication if the most cancers progresses. This research is the primary to scrupulously assess the security and efficacy of that apply in a section 3 randomized scientific trial. The outcomes ship a powerful sign to not sequence PD-1/L1 inhibitors in these sufferers as a result of it supplies no scientific profit and will introduce potential hurt.
Funding:
This research was sponsored by F. Hoffmann-La Roche. Exelixis was a research collaborator.
Supply:
Journal reference:
Pal, S. Ok., et al. (2023) Atezolizumab plus cabozantinib versus cabozantinib monotherapy for sufferers with renal cell carcinoma after development with earlier immune checkpoint inhibitor therapy (CONTACT-03): a multicentre, randomised, open-label, section 3 trial. The Lancet. doi.org/10.1016/S0140-6736(23)00922-4.
